secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001558370-23-016468
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea reports Phase 1 safety data for ATRN-119; no hematologic or liver toxicities; WEE1i ATRN-1051 IND planned Q4 2023
--------------------------------------------------------------------------------

- ATRN-119 Phase 1/2a dose escalation shows no hematologic or liver toxicities across first three cohorts (50, 100, 200 mg) in heavily pretreated solid tumor patients.
- One stable disease observed at 50 mg low dose; dose expansion cohort on track for Q2 2024; currently enrolling 350 mg cohort.
- Pre-clinical data for WEE1i ATRN-1051 shows high selectivity for WEE1 and low off-target activity against PLK kinases; IND submission planned for Q4 2023.
- ATRN-1051 preclinical findings also show limited effects on red blood cell counts, hERG inhibition, and body weight loss compared to other WEE1 inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023016468/0001558370-23-016468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023016468/apre-20231016x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer